Clinicopathologic Characteristics and Survival of Patients with Rare Malignant Ovarian Yolk Sac Tumors: A Population-based Analysis

Abstract

Yolk sac tumors (YSTs) are rare malignant germ cell tumors that usually affect young females. To date, there have been few studies on YSTs. We evaluated the relationship between clinicopathologic characteristics of patients with ovarian YSTs and disease outcome based on Surveillance, Epidemiology, and End Results data. The Kaplan-Meier method and log-rank test were used to evaluate differences in survival rates. Data for 269 patients were analyzed. The incidence of YSTs among ovarian germ cell tumors (OGCTs) cases was 0.4%; median patient age was 22.0 years, and most tumors were unilateral. Patients presented with distant metastasis (37.5%), localized disease (49.1%), and regional spread (8.9%). American Joint Committee on Cancer stage was available for 13 patients (stage IA, n=2; stage IC, n=1; stage IIIA, n=1; stage IIIB, n=3; stage IIIC, n=2; and stage IV, n=4). Survival rates at 1, 3, and 5 years were 91.0%, 84.0%, and 83.2%, respectively, for overall survival (OS) and 92.0%, 85.4%, and 84.5%, respectively, for disease-specific survival (DSS). The 5-year OS and DSS of patients with ovary tumors were 91.5% and 92.9%, respectively, compared to 74.8% and 77.2%, respectively, for those with extra-ovarian spread (P<.001 for both OS and DSS). Age >50 years was associated with shorter OS and DSS (both P<0.001), whereas no associatios of OS and DSS were observed with pathologic grade (P=0.49 for OS and 0.52 for DSS). In summary, YSTs are typically unilateral, of a high grade, and localized to the ovary; extra-ovarian spread has a poor outcome, and postmenopausal women have worse prognosis than premenopausal women.

Keywords

yolk sac tumor / clinical characteristic / prognosis / SEER

References

[1] BoussiosS, AttygalleA, HazellS, et al.. Malignant Ovarian Germ Cell Tumors in Postmenopausal Patients: The Royal Marsden Experience and Literature Review. Anticancer Res, 2015, 35(12): 6713-6722

[2] ShaabanAM, RezvaniM, ElsayesKM, et al.. Ovarian malignant germ cell tumors: cellular classification and clinical and imaging features. Radiographics, 2014, 34(3): 777-801

[3] MoniagaNC, RandallLM. Malignant mixed ovarian germ cell tumor with embryonal component. J Pediatr Adolesc Gynecol, 2011, 24(1): e1-3

[4] YuXJ, ZhangL, LiuZP, et al.. Ovarian malignant mixed germ cell tumor with clear cell carcinoma in a postmenopausal woman. Int J Clin Exp Pathol, 2014, 7(12): 8996-9001

[5] TarantoP, CarvalhoFM, RoithmannS, et al.. Ovarian yolk sac tumor coexisting with epithelial ovarian cancer: An aggressive rare entity. Gynecol Oncol Rep, 2017, 22: 37-39

[6] ShahJP, KumarS, BryantCS, et al.. A population-based analysis of 788 cases of yolk sac tumors: A comparison of males and females. Int J Cancer, 2008, 123(11): 2671-2675

[7] LinSW, HsiehSW, HuangSH, et al.. Yolk sac tumor of endometrium: A case report and literature review. Taiwan J Obstet Gynecol, 2019, 58(6): 846-848

[8] LuT, QiL, MaY, et al.. Primary yolk sac tumor of the endometrium: a case report and review of the literatures. Arch Gynecol Obstet, 2019, 300(5): 1177-1187

[9] SongL, WeiX, WangD, et al.. Primary yolk sac tumor originating from the endometrium: A case report and literature review. Medicine (Baltimore), 2019, 98(15): e15144

[10] WangY, YangJ, YuM, et al.. Ovarian yolk sac tumor in postmenopausal females: A case series and a literature review. Medicine (Baltimore), 2018, 97(33): e11838

[11] RothLM, TalermanA, LevyT, et al.. Ovarian yolk sac tumors in older women arising from epithelial ovarian tumors or with no detectable epithelial component. Int J Gynecol Pathol, 2011, 30(5): 442-451

[12] NasioudisD, SistiG, HolcombK, et al.. Malignant Brenner tumors of the ovary; a population-based analysis. Gynecol Oncol, 2016, 142(1): 44-49

[13] TewariK, CappucciniF, DisaiaPJ, et al.. Malignant germ cell tumors of the ovary. Obstet Gynecol, 2000, 95(1): 128-133

[14] de La Motte RougeT, PautierP, ReyA, et al.. Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases. Eur J Cancer, 2011, 47(2): 175-182

[15] WangX, MaZ, LiY. Ovarian Yolk Sac Tumor: The Experience of a Regional Cancer Center. Int J Gynecol Cancer, 2016, 26(5): 884-891

[16] de la Motte RougeT, PautierP, GenestieC, et al.. Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors. Gynecol Oncol, 2016, 142(3): 452-457

[17] WangX, HeJ, LiY. Ovarian yolk sac tumor in postmenopausal females: a report of five cases and a literature review. Eur J Gynaecol Oncol, 2016, 37(3): 374-379

[18] EuscherED. Germ Cell Tumors of the Female Genital Tract. Surg Pathol Clin, 2019, 12(2): 621-649

[19] ShojaeiH, HongH, RedlineRW. High-level expression of divergent endodermal lineage markers in gonadal and extra-gonadal yolk sac tumors. Mod Pathol, 2016, 29(10): 1278-1288

[20] UlbrightTM. Gonadoblastoma and hepatoid and endometrioid-like yolk sac tumor: an update. Int J Gynecol Pathol, 2014, 33(4): 365-373

[21] KabukcuogluS, ArikD. Ovarian endometrioid carcinoma with yolk sac tumor component in a postmenopausal woman. Eur J Gynaecol Oncol, 2016, 37(6): 867-869

[22] SpearsN, LopesF, StefansdottirA, et al.. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update, 2019, 25(6): 673-693

[23] ChenJ, WangFF, ZhangY, et al.. Oncological and Reproductive Outcomes of Fertility-sparing Surgery in Women with Early-stage Epithelial Ovarian Carcinoma: A Multicenter Retrospective Study. Curr Med Sci, 2020, 40(4): 745-752

[24] Faure ConterC, XiaC, GershensonD, et al.. Ovarian Yolk Sac Tumors; Does Age Matter?. Int J Gynecol Cancer, 2018, 28(1): 77-84

[25] NasioudisD, Chapman-DavisE, FreyMK, et al.. Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base. Gynecol Oncol, 2017, 147(2): 296-301

[26] DunnTN, KhazaeianK, CoffeyDM, et al.. Successful yolk-sac tumor treatment with fertility-sparing partial oophorectomy. Gynecol Oncol Rep, 2019, 27: 22-24